- Home
- GDEV vs RNAC Comparison
GDEV vs RNAC Comparison
Compare GDEV & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEV | RNAC |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | Cyprus | United States |
| Employees | 589 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.9M | 214.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | GDEV | RNAC |
|---|---|---|
| Price | $14.70 | $7.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 1.0K | ★ 183.9K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.89 | $26.02 |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.60 | $5.98 |
| 52 Week High | $42.20 | $16.79 |
Technical Indicators
Market Signals| Indicator | GDEV | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 49.06 |
| Support Level | $14.43 | $6.44 |
| Resistance Level | $17.00 | $8.10 |
| Average True Range (ATR) | 0.74 | 0.87 |
| MACD | -0.18 | 0.04 |
| Stochastic Oscillator | 39.88 | 31.73 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.